SI-BONE reported second-quarter 2026 worldwide revenue of $56.0 million, a 15.2% increase from the prior year, and raised its full-year 2026 revenue guidance to a range of $231 million to $233 million. U.S. revenue grew 14.7% to $53.2 million, while international revenue jumped 25.9% to $2.8 million. The company posted a net loss of $4.1 million, an improvement of 33.6%, and achieved positive adjusted EBITDA of $2.8 million, up 178% from a year ago. Active U.S. physicians increased 19% to 1,715, and cash and equivalents rose sequentially to $145.9 million. SI-BONE also submitted a 510(k) application for a third breakthrough device and highlighted a new CMS reimbursement framework for complex spinal fusion procedures using iFuse Bedrock Granite, effective October 1.
Si-Bone IncRaised 2026 guidance, strong revenue growth, and improved EBITDA.